106 related articles for article (PubMed ID: 24516303)
1. Report of chronic myeloid leukemia SMS Medical College Hospital, Jaipur.
Malhotra H; Sharma R; Singh Y; Chaturvedi H
Indian J Med Paediatr Oncol; 2013 Jul; 34(3):177-9. PubMed ID: 24516303
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Dou XL; Yu L; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):924-931. PubMed ID: 31856442
[No Abstract] [Full Text] [Related]
3. Chronic myeloid leukemia patients in Tunisia: epidemiology and outcome in the imatinib era (a multicentric experience).
Ben Lakhal R; Ghedira H; Bellaaj H; Ben Youssef Y; Menif S; Manai Z; Bedoui M; Lakhal A; M'Sadek F; Elloumi M; Khélif A; Ben Romdhane N; Laatiri MA; Ben Othmen T; Meddeb B
Ann Hematol; 2018 Apr; 97(4):597-604. PubMed ID: 29305630
[TBL] [Abstract][Full Text] [Related]
4. Report of chronic myeloid leukemia in chronic phase from Tata Memorial Hospital, Mumbai, 2002-2008.
Parikh P
Indian J Med Paediatr Oncol; 2013 Jul; 34(3):164-7. PubMed ID: 24516299
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of generic and original imatinib in the treatment of newly diagnosed patients with chronic myelogenous leukemia in chronic phase: a multicenter retrospective clinical study].
Jiang H; Zhi LT; Hou M; Wang JX; Wu DP; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):566-571. PubMed ID: 28810322
[No Abstract] [Full Text] [Related]
6. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).
Nair V; Sharma A; Kotwal J; Bhikshapathy M; Mishra DK; Das S; Sharma S; Kapoor R; Singh J; Nair V; Uday Y; Kotwal A
Med J Armed Forces India; 2014 Oct; 70(4):315-20. PubMed ID: 25382903
[TBL] [Abstract][Full Text] [Related]
8. [Glivec in combination with HA regimen for treatment of 20 patients with Ph chromosome positive acute leukemia].
Meng FY; Zheng WY; Liu XL; Song LL; Xu B; Zhang Y; Huang F
Ai Zheng; 2003 Aug; 22(8):840-3. PubMed ID: 12917031
[TBL] [Abstract][Full Text] [Related]
9. Factors Affecting Early Molecular Response in Chronic Myeloid Leukemia.
Chikkodi SV; Malhotra P; Naseem S; Khadwal A; Prakash G; Sahu KK; Kumari S; Suri V; Varma N; Varma S
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S114-9. PubMed ID: 26297263
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
12. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of imatinib mesylate (glivec) in chronic phase of myeloid leukemia].
Turkina AG; Khoroshko ND; Druzhkova GA; Zingerman BV; Zakharova ES; Chelysheva EIu; Vinogradova OIu; Domracheva EV; Zakharova AV; Kovaleva LG
Ter Arkh; 2003; 75(8):62-7. PubMed ID: 14520855
[TBL] [Abstract][Full Text] [Related]
14. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Castagnetti F; Palandri F; Amabile M; Testoni N; Luatti S; Soverini S; Iacobucci I; Breccia M; Rege Cambrin G; Stagno F; Specchia G; Galieni P; Iuliano F; Pane F; Saglio G; Alimena G; Martinelli G; Baccarani M; Rosti G;
Blood; 2009 Apr; 113(15):3428-34. PubMed ID: 19211938
[TBL] [Abstract][Full Text] [Related]
15. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Hernández-Boluda JC; Cervantes F
Drugs Today (Barc); 2002 Sep; 38(9):601-13. PubMed ID: 12582448
[TBL] [Abstract][Full Text] [Related]
17. Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Medhi K; Raina V; Kumar L; Sharma A; Bakhshi S; Gupta R; Kumar R
Leuk Lymphoma; 2010 Oct; 51(10):1850-4. PubMed ID: 20849386
[TBL] [Abstract][Full Text] [Related]
18. [Compliance to imatinib therapy in patients with chronic myeloid leukemia in Henan province and its influence on cytogenetic response at 12 months].
Li Z; Zhang Y; Zhou J; Li MJ; Wang J; Zhao HF; Gui RR; Zu YL; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):581-4. PubMed ID: 27535858
[TBL] [Abstract][Full Text] [Related]
19. Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
Dou X; Qin Y; Lai Y; Shi H; Huang X; Jiang Q
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):e304-e315. PubMed ID: 32209331
[TBL] [Abstract][Full Text] [Related]
20. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]